Blood Cancers | Tumor

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025, 3:00pm

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

March 22nd 2025, 6:00pm

Article

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

March 21st 2025, 4:00pm

Article

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

March 18th 2025, 9:00pm

Article

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

March 18th 2025, 4:00pm

Article

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.